BiotechTube
Axogen

Axogen

AXGN
United States

Axogen's mission is to restore health and improve quality of life by making the restoration of peripheral nerve function an expected standard of care. With over 15 years of experience, the company provides a comprehensive portfolio of nerve repair solutions, primarily used by hand, reconstructive plastic, and oral/maxillofacial surgeons. Recent clinical data from a meta-analysis of over 1,550 nerve repairs demonstrates the comparability of outcomes between its allograft and the traditional autograft, supporting its position as a new standard. The company is led by an experienced management team and is publicly traded.

axogeninc.com

AXGN · Stock Price

USD 32.61+13.81 (+73.46%)
Market Cap: $1.7B

Historical price data

AI Company Overview

Axogen's mission is to restore health and improve quality of life by making the restoration of peripheral nerve function an expected standard of care. With over 15 years of experience, the company provides a comprehensive portfolio of nerve repair solutions, primarily used by hand, reconstructive plastic, and oral/maxillofacial surgeons. Recent clinical data from a meta-analysis of over 1,550 nerve repairs demonstrates the comparability of outcomes between its allograft and the traditional autograft, supporting its position as a new standard. The company is led by an experienced management team and is publicly traded.

Peripheral Nerve InjuryTraumaChronic PainNeuroma

Technology Platform

Proprietary platform for processing human donor nerve tissue to create ready-to-use allografts, combined with a suite of protective and connective matrices for comprehensive nerve repair surgery.

Pipeline

1
1 drug in pipeline1 in Phase 3
DrugIndicationStageWatch
Processed Nerve Allograft (human)Peripheral Nerve DiscontinuitiesPhase 3

Funding History

3
Total raised:$60M
IPO$30MNov 8, 2012
Series B$20MJun 15, 2008
Series A$10MJun 15, 2006

Opportunities

Growth opportunities include displacing the autograft standard of care through continued clinical evidence and surgeon education, expanding into new surgical specialties (e.g., neurosurgery, orthopedics), and pursuing international market expansion.
Further product innovation within the nerve repair ecosystem also presents a significant opportunity.

Risk Factors

Key risks include slower-than-expected surgeon adoption and market shift away from autografts, reimbursement challenges from payers, increased competition from synthetic conduits or new technologies, and supply chain vulnerabilities related to human donor tissue.

Competitive Landscape

Axogen primarily competes against the entrenched autograft procedure and synthetic nerve conduits (e.g., from Integra LifeSciences). Its differentiation is based on a comprehensive product portfolio, robust clinical data showing comparability to autograft, and a dedicated commercial focus on nerve repair.